Metacel Pharmaceuticals’ Ozobax (baclofen) Receives the US FDA’s Approval for Spasticity Due to Multiple Sclerosis

 Metacel Pharmaceuticals’ Ozobax (baclofen) Receives the US FDA’s Approval for Spasticity Due to Multiple Sclerosis

Metacel Pharmaceuticals’ Ozobax (baclofen) Receives the US FDA’s Approval for Spasticity Due to Multiple Sclerosis

Shots:

  • Ozabax is a gamma-aminobutyric acid (GABA-ergic) agonist orally administered low dosage and is available as a 5mg/5 ml oral solution
  • The efficacy of Ozobax is based on the bioavailability study evaluated in healthy adults in comparison with Baclofen oral tablets
  • Metacel is also planning to launch Ozobax with pending plans. Ozobax has a warning of for its withdrawal can lead to neonatal withdrawal symptoms, drowsiness and sedation, poor tolerability in stroke patients, schizophrenia, or confusional states, and ovarian cysts

Click here to­ read full press release/ article | Ref: OptumRx | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post